Search

117 Result(s)

Group of scientists from the Chemical Development department at Boehringer Ingelheim gathering in the kilolab facilities, where the first kilogram quantities of the drug substance is manufactured
Science Stories

Targeting MDM2-p53 in cancer: The story of brigimadlin

Our perseverance and passion for science led to the discovery of brigimadlin, our MDM2-p53 antagonist. It is being clinically investigated as a potential treatment for dedifferentiated liposarcoma, a rare cancer with significant unmet needs.
Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim in the new “stop motion” video.
History

History Video

Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim.
bildmarke_um_1900.jpeg
History

History of the Logo

The logo used by Boehringer Ingelheim today is a stylised depiction of the central section of the imperial palace of Charlemagne.
portrait of a lung cancer patient
Lung Cancer

Keith and Heather’s Story

Having lost his left lung to cancer, Keith faced a challenging road to recovery but didn’t allow it to limit his lifestyle or ambitions.